About Aduro Biotech
Aduro Biotech, Inc. is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. Its LADD product candidates include CRS-207, ADU-623, ADU-741 and ADU-214. Its STING Activator product candidates include ADU-S100. Its LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Its STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. Its B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ADRO
- Previous Close: $11.15
- 50 Day Moving Average: $11.49
- 200 Day Moving Average: $12.59
- 52-Week Range: $7.26 - $17.72
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.57
- P/E Growth: 0.07
- Market Cap: $762.52M
- Outstanding Shares: 67,182,000
- Beta: 3.83
- Net Margins: -72.04%
- Return on Equity: -23.45%
- Return on Assets: -12.40%
Companies Related to Aduro Biotech:
- Current Ratio: 11.11%
- Quick Ratio: 11.11%
What is Aduro Biotech's stock symbol?
Aduro Biotech trades on the NASDAQ under the ticker symbol "ADRO."
Where is Aduro Biotech's stock going? Where will Aduro Biotech's stock price be in 2017?
5 brokers have issued 12 month price targets for Aduro Biotech's shares. Their forecasts range from $14.00 to $30.00. On average, they expect Aduro Biotech's stock price to reach $19.60 in the next twelve months.
When will Aduro Biotech announce their earnings?
Aduro Biotech is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
Who owns Aduro Biotech stock?
Aduro Biotech's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (4.24%), State Street Corp (0.85%), Clough Capital Partners L P (0.49%), Baillie Gifford & Co. (0.43%), Artal Group S.A. (0.15%) and Russell Investments Group Ltd. (0.04%). Company insiders that own Aduro Biotech stock include Blaine Templeman, Dirk G Brockstedt, Gregory W Schafer, Jennifer Lew, Ross Haghighat, Stephen T Isaacs, Thomas W Dubensky, Venture (Vi) Inves Morningside and William Mariner Greenman.
Who sold Aduro Biotech stock? Who is selling Aduro Biotech stock?
Aduro Biotech's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and First Republic Investment Management Inc.. Company insiders that have sold Aduro Biotech stock in the last year include Blaine Templeman, Dirk G Brockstedt, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky.
Who bought Aduro Biotech stock? Who is buying Aduro Biotech stock?
Aduro Biotech's stock was acquired by a variety of institutional investors in the last quarter, including Clough Capital Partners L P, Russell Investments Group Ltd., Renaissance Technologies LLC, Tudor Investment Corp Et Al and State Street Corp. Company insiders that have bought Aduro Biotech stock in the last two years include Jennifer Lew, Venture (Vi) Inves Morningside and William Mariner Greenman.
How do I buy Aduro Biotech stock?
Shares of Aduro Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Aduro Biotech stock cost?
One share of Aduro Biotech stock can currently be purchased for approximately $11.35.